Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

red yeast rice and Reduced Atherosclerotic Cardiovascular Disease Event

Doses used in studies

mg/day: 3 (median 3, IQR 3–3) — 1 study

Safety in these studies

Overall tolerabilityReported
RYR at a dose that provides about 3 mg/d of monacolin K is well tolerated, with an adverse event profile similar to that of low-dose statins.
from: Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterole

1 of 1 paper

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review.
- 2023-05-12
- Review
- Nutrients 15(10)
- - Arrigo F G Cicero
  - Federica Fogacci
  - Anca Pantea Stoian
  - Peter P Toth
- PubMed: 37242171
- DOI: 10.3390/nu15102288
2 Insights on
- Reduced Atherosclerotic Cardiovascular Disease Event
- Moderate evidence
- Rigorous Journal
- Clinical
RYR has also demonstrated beneficial reductions of up to 45% versus placebo in the risk of ASCVD events in secondary prevention studies.
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
about 3 mg/d of monacolin K